

Memorandum

To: Gold Coast Health Plan Providers

From: Yoonhee Kim, Pharm.D., APh, Interim Director of Pharmacy Services

Re: **Physician Administered Drugs (PAD) List Changes**

Date: November 20, 2024

Gold Coast Health Plan (GCHP), with direction from the state Department of Health Care Services (DHCS) and the Pharmacy & Therapeutics (P&T) Committee, updates the Physician Administered Drugs (PAD) list quarterly. This notice is to inform you of the approved changes from the May 16, 2024, and Aug. 15, 2024, P&T committee meetings, which will be effective March 1, 2025.

PADs through GCHP's Medical Drug Benefit include all infused, injectable drugs provided or administered to a member that is billed by a provider on a medical claim by a Procedure Code (e.g., J-Code). Certain physician administered drugs require prior authorization (PA) to ensure medical necessity prior to receiving the drug therapy. Any request for a PAD via Procedure Code (e.g., J-Code) requiring a PA, administered at a provider's office or infusion / hospital facility, must be submitted as a treatment authorization request using the [Prior Authorization Treatment Request Form](#).

The current PAD list is posted on GCHP website on the [Medical Drug Benefit for Providers](#) page. The updated PAD list, with the changes below, and the accompanying clinical guidelines are scheduled to be posted on the GCHP website by March 1, 2025.

Changes to the PAD list effective, March 1, 2025:

HCPCS	Generic Name	Brand Name	Changes
J9035	Bevacizumab	Avastin	Removed
J0491	Anifrolumab	Saphnelo	Added
J0485	Belatacept	Nulojix	Added
J0565	Bezlotoxumab	Zinplava	Added
J0584	Burosumab	Crysvita	Added
J0638	Canakinumab	Ilaris	Added
J0717	Certolizumab pegol	Cimzia	Added
J1096	Dexamethasone Ophthalmic insert	Dextenza	Added
J1300	Eculizumab	Soliris	Added
J3032	Eptinezumab	Vyepti	Added
J1305	Evinacumab	Evkeeza	Added
J7313	Fluocinolone intravitreal implant	Iluvien	Added
J7314	Fluocinolone intravitreal implant	Yutiq	Added
J1602	Golimumab	Simponi Aria	Added

J7318	Hyaluronic acid derivative, intra-articular injection	Durolane	Added
J7322	Hyaluronic acid derivative, intra-articular injection	Hymovis	Added
J7327	Hyaluronic acid derivative, intra-articular injection	Monovisc	Added
J7328	Hyaluronic acid derivative, intra-articular injection	Gelsyn-3	Added
J7329	Hyaluronic acid derivative, intra-articular injection	TriVisc	Added
J7331	Hyaluronic acid derivative, intra-articular injection	Synojynt	Added
J7332	Hyaluronic acid derivative, intra-articular injection	Triluron	Added
J7320	Hyaluronic acid derivative, intra-articular injection	GenVisc 850	Added
J1745	Infliximab	Remicade	Added
Q5104	Infliximab-abda	Renflexis	Added
Q5121	Infliximab-axxq	Avsola	Added
Q5103	Infliximab-dyyb	Inflectra	Added
Q5109	Infliximab-qbtx	Ixifi	Added
J2181	Mepolizumab	Nucala	Added
J2323	Natalizumab	Tysabri	Added
J2350	Ocrelizumab	Ocrevus	Added
Q9093	Ranibizumab	Susvimo	Added
J2249	Reslizumab	Cinqair	Added
J2327	Risankizumab	Skyrizi	Added
J3111	Romosozumab	Evenity	Added
J1747	Spesolimab	Spevigo	Added
J3241	Teprotumumab	Tepezza	Added
J2356	Tezepelumab	Tezspire	Added
J3299	Triamcinolone suprachoroidal	Xipere	Added
J2329	Ublituximab	Briumvi	Added
J3358	Ustekinumab	Stelara	Added
J3380	Vedolizumab	Entyvio	Added

Removed – The medication is removed from the PAD list and PA is not needed.

Added – The medication is added to the PAD list and PA is needed.

If you have any questions, please contact the GCHP's Pharmacy Services Department at Pharmacy@goldchp.org.